FENNEC PHARMACEUTICALS INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
FENNEC PHARMACEUTICALS INC. (FENC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $2.97 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2024-03-29
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $2.97M, a 64.09% increase from fiscal 2022.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $1.81M, a 2916.67% increase from fiscal 2021.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2021 was $60.00K, a 97.86% decline from fiscal 2020.
- FENNEC PHARMACEUTICALS INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2020 was $2.80M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|
| 2023-12-31 | $2.97M 10-K · filed 2024-03-29 |
| 2022-12-31 | $1.81M 10-K · filed 2023-03-29 |
| 2021-12-31 | $60.00K 10-K · filed 2022-02-28 |
| 2020-12-31 | $2.80M 10-K · filed 2021-03-30 |
| 2019-12-31 | $0.00 10-K · filed 2020-02-14 |
| 2018-12-31 | $1.10M 10-K · filed 2019-03-15 |
| 2017-12-31 | $1.83M 10-K · filed 2018-03-28 |
| 2016-12-31 | $3.00K 10-K · filed 2017-03-29 |
| 2015-12-31 | $62.00K 10-K · filed 2016-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |